Thus, p53-armed oncolytic virotherapy appears to be a promising antitumor strategy that strongly induces apoptosis and autophagy in KRAS/BRAF-mutant CRC cells by suppressing the EGFR-MEK-ERK and AKT-mTOR signaling pathways. The gene discussed is TP53; the disease is colorectal carcinoma.